MemoDero
Treating Fear-related Disorders
Company Overview
Snapshot
Founded in January 2015 by Professor Raphael Lamprecht, MemoDero operates with 1–10 employees. The company has secured funding across one disclosed round from one investor. MemoDero is developing a first-in-class drug candidate to prevent debilitating consequences of fear-related diseases, such as post-traumatic stress disorder.
Business overview
MemoDero is a Health Tech & Life Sciences company focused on developing pharmaceutical solutions for fear-related disorders. The company's core technology involves the drug candidate pep-EphrinA4, designed to inhibit the development of fear memory following traumatic events. MemoDero operates within the Pharmaceuticals & Diagnostics sector, targeting the mental health market with a B2B business model for pharmaceutical companies globally.
Log in to access full profile ›Company Intelligence Q&A
- What is MemoDero's primary focus?
- MemoDero is developing a first-in-class drug candidate to prevent debilitating consequences of fear-related diseases, such as post-traumatic stress disorder (PTSD).
- When was MemoDero founded?
- MemoDero was founded in January 2015.
- Who is the scientific founder of MemoDero?
- Professor Raphael Lamprecht is the scientific founder of MemoDero.
- What is the name of the drug candidate being developed by MemoDero?
- MemoDero is developing the drug candidate pep-EphrinA4, aimed at reducing or preventing the debilitating consequences of fearful memories.
- What is the status of MemoDero?
- MemoDero ceased to operate in February 2022.